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Abstract
Background: Fear of cancer recurrence (FCR) is common in people affected by breast cancer. FCR is associated
with increased health service and medication use, anxiety, depression and reduced quality of life. Existing
interventions for FCR are time and resource intensive, making implementation in a National Health Service (NHS)
setting challenging. To effectively manage FCR in current clinical practice, less intensive FCR interventions are
required. Mini-AFTERc is a structured 30-min counselling intervention delivered over the telephone and is designed
to normalise moderate FCR levels by targeting unhelpful behaviours and misconceptions about cancer recurrence.
This multi-centre non-randomised controlled pilot trial will investigate the feasibility of delivering the Mini-AFTERc
intervention, its acceptability and usefulness, in relation to specialist breast cancer nurses (SBCNs) and patients. This
protocol describes the rationale, methods and analysis plan for this pilot trial of the Mini-AFTERc intervention in
everyday practice.
Methods: This study will run in four breast cancer centres in NHS Scotland, two intervention and two control
centres. SBCNs at intervention centres will be trained to deliver the Mini-AFTERc intervention. Female patients who
have completed primary breast cancer treatment in the previous 6 months will be screened for moderate FCR
(FCR4 score: 10‑14). Participants at intervention centres will receive the Mini-AFTERc intervention within 2 weeks of
recruitment. SBCNs will audio record the intervention telephone discussions with participants. Fidelity of
intervention implementation will be assessed from audio recordings. All participants will complete three separate
follow-up questionnaires assessing changes in FCR, anxiety, depression and quality of life over 3 months.
Normalisation process theory (NPT) will form the framework for semi-structured interviews with 20% of patients and
all SBCNs. Interviews will explore participants’ experience of the study, acceptability and usefulness of the
intervention and factors influencing implementation within clinical practice. The ADePT process will be adopted to
systematically problem solve and refine the trial design.
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Discussion: Findings will provide evidence for the potential effectiveness, fidelity, acceptability and practicality of the
Mini-AFTERc intervention, and will inform the design and development of a large randomised controlled trial (RCT).
Trial registration: ClinicalTrials.gov: NCT0376382. Registered 4th December 2018, https://clinicaltrials.gov/ct2/show/
NCT03763825
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Background
Fear of cancer recurrence (FCR) is prevalent amongst
people affected by breast cancer, with 60% or higher
claiming they want to speak with their cancer care team
to discuss their fears [1]. Fear of cancer recurrence is
defined as “Fear, worry, or concern relating to the possi-
bility that cancer will come back or progress” [2]. FCR is
an understandable reaction to surviving a serious illness;
however, when it becomes severe it can produce un-
wanted effects including loss of concentration, lowered
quality of life, propensity to depression as well as in-
creased health service utilisation, medication and over
frequent self-examination [3–6]. FCR results from the
activation of certain cognitions, beliefs and emotions
that an individual acquires following cancer diagnosis
and treatment [7]. Therefore, psychological interventions
are needed to assist patients to better cope with FCR [6].
Intensive psychological interventions for FCR are
available, including ConquerFear [8], SWORD [9] and
AFTER [10]. However, such interventions are designed
for those with ‘severe’ FCR and are highly resource and
time intensive. In the UK, a national lack of funding and
highly trained mental health professionals (psychologists,
psychiatrists, etc.) across the National Health Service
(NHS) [11] would make implementing such intensive in-
terventions difficult. Nevertheless, some form of inter-
vention is crucial as once FCR becomes severe, it is
particularly challenging to reduce [6]. Interventions may
also reduce costs and pressure on specialist services be-
cause patients with high FCR use more specialist ser-
vices [12, 13].
A recent randomised control trial of an online-only
intervention (CAREST-trial) to support individuals to
manage elevated FCR found that the intervention pro-
duced no significant reduction in FCR [14]. This finding
demonstrates that online self-management approaches
may not effectively manage FCR and highlights the
potential need for interpersonal interaction to improve
FCR. A review of FCR interventions delivered by non-
mental health professionals concluded that professionals
other than psychologists can deliver psychological and
counselling interventions to reduce FCR in patients
affected by cancer [15]. Specialist cancer nurses are
potentially ideal candidates to deliver FCR interventions
as they provide psychological support to patients from
the point of cancer diagnosis onwards [15]. Given this evi-
dence, it is important that further research is undertaken
to develop and test less intensive FCR interventions that
can be delivered by non-mental health professionals and
are suitable to implement into current clinical practice.
The Mini-AFTERc intervention is a cognitive behav-
ioural intervention based on the self-regulation model
(SRM) of illness cognitions [16]. It is a less intensive ver-
sion of the AFTER intervention [10] and is designed to be
delivered by trained specialist cancer nurses in approxi-
mately 30min [17]. Mini-AFTERc aims to reduce FCR in
people affected by cancer by targeting inappropriate or
unhelpful behaviours (e.g. twice daily self-examination),
and misconceptions about cancer recurrence. A common
example of misconception is that patients will interpret
new symptoms or sensation, such as acute pain, numbness
or tingling, as cancer recurrence. Before the cancer diag-
nosis, patients may have interpreted these new experi-
ences as harmless, but post-diagnosis patients may
assume that they have sinister connotations. The interven-
tion does not intend to dispel fears entirely or to reduce
unduly attention to symptom change and appropriate self-
examination behaviours.
A feasibility study of the Mini-AFTERc intervention was
conducted within one breast service in NHS Scotland
[17]. A sample of 16 patients who had completed breast
cancer treatment reported a significant decrease in FCR at
1 week after the intervention was delivered. In this setting,
specialist breast cancer nurses (SBCNs) who were trained
in and delivered Mini-AFTERc found the intervention
manageable and easy to follow. SBCNs also believed the
intervention may be useful for reducing the demand on
their time and resources by addressing FCR before it be-
comes severe [17]. Additionally, a mixed-methods study
with 90 UK-based SBCNs aimed to determine the accept-
ability of implementing the Mini-AFTERc intervention
into current practice [18]. SBCNs were asked how FCR
was currently identified, assessed and supported, and their
willingness to implement the Mini-AFTERc, via an online
survey and semi-structured interviews. FCR was reported
to be an important issue by SBCNs, but their reported
practices to identify, assess and support FCR were highly
variable. SBCNs viewed the Mini-AFTERc intervention
favourably and believed it would enhance their skills in
the managing FCR [18]. Following the favourable
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outcomes of these studies, additional research is required
to assess the feasibility and acceptability of the Mini-
AFTERc intervention amongst a larger sample of patients.
Methods
Aim and objectives
The aim of this pilot trial is to investigate the acceptability
and feasibility of delivering the Mini-AFTERc intervention
in every day clinical practice. The objectives are as follows:
1. To develop a procedure for training SBCNs in the
delivery of the Mini-AFTERc intervention.
2. To assess the acceptability of the Mini-AFTERc
intervention for SBCNs and patients and the
feasibility of introducing the intervention into
current NHS service provision.
3. To apply a formal decision-making framework to
identify potential difficulties in the implementation
of the pilot trial and appraise solutions prior to the
development of a full-randomised control trial.
The Mini-AFTERc intervention
The Mini-AFTERc intervention is a manualised struc-
tured discussion plan comprising of five topics which
are discussed during a 30-min telephone discussion. The
Mini-AFTERc intervention was designed to target spe-
cifically the antecedents within the cognitive formulation
of FCR developed by Lee-Jones et al. [7].
The first stage of the Mini-AFTERc intervention is as-
sessment. The assessment stage aims to establish an un-
derstanding of the participant’s experiences and
symptoms of FCR and to tailor the subsequent interven-
tion discussion to the participant’s needs. Assessment
processes are common to all cognitive behavioural-based
interventions [19]. The Mini-AFTERc assessment is
structured (Fig. 1) to ensure that all aspects of the four
Fig. 1 Topics covered during the Mini-AFTERc assessment phase
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primary discussion topics (family, thoughts and feelings,
expectations, return of cancer) are raised with the partici-
pant. This allows the individual delivering the intervention
to prioritise and target one or two of the discussion topics
for further detailed discussion.
Family is the first detailed discussion topic of the
Mini-AFTERc intervention. Social constraints have been
shown to increase FCR [20] and present a possible path-
way to FCR development, therefore this topic focuses on
communication processes with the participant’s family
and friends. The quality of their participant’s relation-
ship with family and friends is assessed and whether the
participant has an individual who they can have open
discussions with about their thoughts and feelings (a
confidante). The individual delivering the intervention
may encourage the participant to have more open dis-
cussion with family and friends about how they are feel-
ing and/or to explore other means of social support (e.g.
cancer support groups).
The second detailed discussion topic is thoughts and
feelings. This topic concentrates on the identification of
symptoms experienced during treatment and those after
treatment completion. This phenomenon has been iden-
tified previously in people affected by breast cancer [21].
Participants who associate symptoms (i.e. ‘triggers’) as
indicators of cancer returning are invited to describe
these symptoms in greater detail. The individual deliver-
ing the intervention may normalise the participants’ ex-
periences (i.e. “many people experience these symptoms
after treatment”); an approach which has been used ef-
fectively in the field of psychosis [22]. They may also
provide additional information to persuade the partici-
pant that such symptoms are not necessarily indicative
of cancer returning [23].
The third detailed discussion topic is expectations. This
topic invites participants to relate their concerns about
follow-up visits, scans and self-awareness/checking. Previ-
ous evidence indicates that expectations about the outcome
of upcoming out-patient visits [24] and/or self-examination
behaviours [21] may heighten FCR. Some individuals may
engage in these behaviours as an FCR management strat-
egy, conforming to a cognitive behavioural model. The indi-
vidual delivering the intervention may assist participants to
understand their reactions to their behaviour [19] and rec-
ommend graded behaviour change.
The fourth discussion topic is return of cancer and fo-
cuses on the participants thought about the future. The
individual delivering the intervention may normalise the
participants’ concerns about the future. Through a
process of brief graded exposure [25] to the possibility of
the cancer returning, they may encourage the participant
to express their anxieties openly.
The Mini-AFTERc discussion concludes with a short
summary of issues covered and suggested recommendations
or action plans discussed during the telephone conversation.
Participants will also be given the opportunity to ask any
questions they may have. Thirty minutes is considered the
optimal time required to fully address two of the discussion
topics. Nurses will be advised to complete the discussion
within 30min however this is not categorical. Nurses will be
encouraged to use their discretion to extend the discussion
beyond 30min. The duration of discussions will be recorded
as part of this study. If the nurses have any outstanding con-
cerns about a patient after their discussion that they think
require more extensive discussion then they are advised to
refer the patient for additional psychological support
through the usual pathway at their cancer centre.
Patient FCR will be monitored after the intervention
has been delivered as part of this study using a self-
report questionnaire. Any patients who display increas-
ing FCR will be offered additional support at the end of
the study. This support may include one-to-one counsel-
ling at the breast cancer centre or the offer of a referral
to specialist psychological services. All referrals and of-
fers of additional support will be recorded as part of this
pilot trial.
Trial design
This study is a non-randomised controlled pilot trial
conducted within four breast cancer centres in NHS
Scotland. The Mini-AFTERc intervention will be deliv-
ered at two of the sites in addition to standard care and
compared to standard care alone delivered at the two
control sites. The selection of cancer centres was de-
pendant on the proximity of the research institutions
and local knowledge of service provision. Guidance in
relation to breast cancer follow-up after primary diagno-
sis is inconsistent [18]. Consequently, standard care (i.e.
follow-up and support for patients once they have
completed primary cancer treatment) can vary between
cancer centres, in terms of timing and types of support
offered. SBCNs at the intervention sites will be recruited
and trained to deliver the Mini-AFTERc intervention
using a pre-determined training programme, which will
be further developed and refined with feedback from
participating SBCNs during this trial.
Participants will be recruited from hospital clinics and
over the telephone. Participants from intervention cen-
tres will receive an intervention telephone call within 2
weeks of recruitment. All participants (intervention and
control) will be asked to report their FCR, mood and
quality of life over a three-month follow-up period
(Fig. 2). A bespoke smartphone application, already
designed to collection questionnaire responses form pa-
tients, will also be tested as part of this pilot trial.
Patient involvement is a core principle in the design
and implementation of this pilot trial. Elspeth Banks
(EB) is a representative of the National Cancer Research
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Institute (NCRI) and the Independent Cancer Patients’
Voice (ICPV). EB was regularly consulted during the de-
sign of this pilot trial and on the acceptability of this re-
search from a patient’s perspective. EB will continue to
be a key partner throughout the implementation of this
trial and the analysis of the findings.
This pilot trial will be conducted in three consecutive
phases: preparatory phase, intervention delivery and data
collection phase, and evaluation phase (Table 1).
Phase 1: Preparatory
The purpose of phase 1 is to develop the Mini-AFTERc
intervention training programme for SBCN and to de-
liver the training at cancer centres that will be delivering
the intervention. Additionally, a bespoke Mini-AFTERc
smartphone application for the collection of research
data will be developed and piloted during phase 1.
Mini-AFTERc intervention training
A detailed Mini-AFTERc training manual was devel-
oped for the previous Mini-AFTERc feasibility study
[17]. This manual provides SBCNs with a detailed over-
view of the theory and structure of the Mini-AFTERc
intervention, as well as providing examples of questions
and prompts to aid SBCNs to facilitate intervention
discussions with patients. The planned structure of the
training sessions is as follows:
Session 1. Present an overview of the Mini-AFTERc
intervention, fear of cancer recurrence and the purpose of
the phone call. Trainees will be provided with a detailed
explanation of the training manual, including the structure
of Mini-AFTERc intervention and transcript examples of
how to deliver the different stages of the intervention from
previously recorded Mini-AFTERc telephone discussions
(from the previous feasibility study [17]).
Session 2. An interactive workshop using roleplay sce-
narios representing each section of the Mini-AFTERc
intervention. For each scenario, the initial stage is
scripted and then SBCNs continue the conversation un-
scripted according to the Mini-AFTERc principles.
SBCNs can “pause” and “restart” the discussion at any
point to confer, clarify or reflect on their conversations
and gain support and guidance from the trainers. This
session also provides SBCNs with training in the use of
the recording equipment and data collection require-
ments prior to beginning a Mini-AFTERc discussion.
Session 3. This session aims to simulate the Mini-
AFTERc telephone discussion by using a patient expert
and use of the recording equipment. Case studies have
been written for the simulated patient. These scenarios
were based on the clinical experience of GH. SBCNs de-
liver the Mini-AFTERc intervention as they would in
their clinical practice setting; in a private room, over the
telephone and using the audio recording devices. The
Fig. 2 Mini-AFTERc pilot trial timeline, following SPIRIT [26]
Table 1 Phases of the Mini-AFTERc pilot trial
Phase Overview of procedures
Phase 1: Preparatory • Development of SBCN intervention training programme
• Delivery of training programme via a workshop for consenting SBCN in intervention centres
• Development and testing of Mini-AFTERc smartphone application
Phase 2: Intervention delivery and data collection • Screening and recruitment of patients at all centres
• Intervention delivery at intervention centres
• Collection of patient demographic and outcome data via smartphone app at baseline and
3 follow-up time points
• Semi-structured interviews with SBCNs and sample of patient participants
Phase 3: Evaluation • Statistical analysis of outcome data
• Fidelity analysis of SBCNs adherence to intervention
• Use of NPT in analysis of patient and nurse semi-structured interviews
• Trial evaluation following the ADePT process
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SBCNs will receive a debrief from the lead researcher.
Following a review of these recordings, a future meeting
will be organised with each nurse participant to provide
feedback.
All training sessions will be delivered by the research
team based in Scotland. Following the formal training
sessions, SBCNs will be offered continued support via
email and telephone from the research team for the dur-
ation of the trial. Nurses will have frequent interaction
with the research team during the trial and will be en-
couraged to feedback any challenges or difficulties they
encounter during the trial. The research team will work
with the nurses to find a suitable solution.
Smartphone application development
A bespoke smartphone application (app) will be de-
signed to support data collection during this pilot trial.
The app will be collaboratively developed by research
team members in the Schools of Medicine and Com-
puter Science at the University of St Andrews. The app
provides a secure site for participants to electronically
submit questionnaire responses throughout the trial.
The app will send notifications to participants to prompt
them to complete questionnaires at the pre-defined time
points. A prototype of the app has been developed
(Fig. 3). Early prototypes have been reviewed by the pa-
tient expert on the research team (EB) and informed its
development. Throughout phase 1, the design and func-
tionality will be continuously reviewed by all members
of the research team.
Phase 2: Intervention delivery and data collection
Eligibility and recruitment
Mini-AFTERc is designed for patients with moderate
FCR, therefore consented patients will complete the fear
of cancer recurrence 4-item (FCR4) measure [27] to de-
termine their eligibility (score range: 10‑14). The FCR4
has been previously shown to be reliable (α 0.93, 95% CI
0.91‑0.94) [27]. Any patient who score > 14 (i.e. high) on
the FCR4 will be offered a referral onto psychological
support services, in line with standard practice at each
cancer centre. Additional patient eligibility criteria for
screening are broad to ensure external validity of the
sample. Patients will be eligible for screening if (1) they
have completed their primary cancer treatment for
breast cancer, (2) are cancer-free, (3) are female, (4) are
aged 18 or over and (5) their responsible clinician agrees
to their participation. Patients will be ineligible for
screening if they have not completed their cancer treat-
ment, are not cancer-free, are male and/or are receiving
treatment for a diagnosed psychotic disorder that is
known to the cancer service.
Potential participants will be identified in the cancer
centres via patient appointment systems. A one-page
study information letter will be sent to potential partici-
pants prior to their follow-up appointment or end of
treatment review. There are two potential recruitment
and consent processes:
Process 1. Participants attending in person will be in-
vited to speak directly with a researcher about the study
Fig. 3 Screen captures of prototype Mini-AFTERc smartphone application
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in the clinic. This meeting will provide study informa-
tion and consent will be taken to participate in the trial.
Process 2. Participants not attending in person will
have the study introduced by their cancer care team and
be asked to consent to their contact details being shared
with the research team. The researchers will contact po-
tential participants to discuss the trial, provide additional
information and consent. All study information and con-
sent forms will be mailed. Consent forms will be re-
quired to be returned before participants can continue
in the study.
Sample size
The trial aims to recruit 130 breast cancer patients,
approximately 33 patients at each breast cancer centre. Re-
searchers will screen patients until 65 patients have been
recruited to the intervention group and 65 patients to the
control group. Screening will continue until the target
sample size has been reached. The anticipated recruitment
period will take place over 12months. An effect size of 0.5
at 0.85 power would require a sample of 130 patients to
robustly demonstrate any effect of the intervention on
patients’ fear of cancer recurrence, assuming a standard de-
viation of 7 between pre and post FCR measures, derived
from a previous feasibility study [17], and an attrition rate
of 30%.
Screening and baseline assessment
Screening will be conducted with the fear of cancer re-
currence 4-item (FCR4) measure [27]. Participant demo-
graphical information, including age (in years), cancer
treatments received, education, employment and living
situation, will also be collected during screening but eli-
gibility will not depend on this information. A score of
≥ 10 and < 15 in the FCR4 is defined as ‘moderate’ FCR.
Patients will be excluded from the trial if they score ‘low’
(< 10) or ‘high’ (≥ 15) on the FCR4. It is anticipated that
3 in 10 patients will obtain an FCR4 scoring in the mod-
erate range (60th percentile) therefore approximately
440 participants will be required to be screened to ob-
tain the required sample of 130. If eligible after screen-
ing, participants will be asked to complete the Hospital
Anxiety and Depression Scale (HADS) [28] and the
Euro-Qol 5-dimension health-related quality of life
measure (EQ-5D-5 L) [29] at baseline. All initial screen-
ing and baseline data collection will be completed by the
researcher and the participant either face to face or over
the telephone.
Intervention delivery
Patients will receive the Mini-AFTERc intervention tele-
phone call from one of the trained breast care nurses
within 2 weeks of screening. Patients will be given a date
and time for the telephone call from the researcher on
the day of screening. Telephone calls will last approxi-
mately 30 min and will be audio recorded by the nurse.
Nurses may have consulted patients during their treat-
ment and have access to their records during the inter-
vention discussion.
Follow-up assessment
Participants in the intervention group will complete the
consultation and relational empathy (CARE) [30] and the
medical interview satisfaction scale (MISS) [31] within 1 or
2 weeks following their telephone discussion to measure ac-
ceptability. Additionally, the intervention group will
complete the HADS and EQ-5D measures at 2 weeks, 1
month and 3months following the intervention telephone
discussion. Participants in the control group will complete
the same measures at 3 weeks, 5 weeks and 13 weeks fol-
lowing baseline. The minor time point differences are to
ensure data are collected at a similar time point in the study
for intervention and control groups, allowing time for the
intervention to be delivered. See supplementary file 1 for a
comprehensive overview of all patient outcomes assessed in
with research questionnaires.
All follow-up measures will be accessed by patients
using the smartphone app. The app will be installed on
the participants’ mobile phone after recruitment. To ac-
commodate participants who cannot attend in person or
do not have a compatible smartphone, a web browser
version of the app has been developed or paper versions
of the questionnaires can be made available. Alternative
arrangements have been put in place to distribute paper
copies at the different time points, due to technical diffi-
culties with the smartphone application or participant
preference.
Semi-structured interviews
Interviews with patients will cover their experiences dur-
ing the recruitment process and during data collection,
including timing and methods of collection (mobile
phone app or paper-based). Patients in the intervention
group will be asked about the usefulness and impact of
the Mini-AFTERc intervention, including the method of
delivery (telephone call), and ways to improve the inter-
vention. Interviews with SBCNs will explore their views
on the usefulness and impact of the intervention and
areas where more help was required.
A 20% sample of patients (approximately 26) will be
interviewed. A sampling matrix (see supplementary file 2)
will ensure a representative sample of patients is recruited
based on age, research site, trial group (control/inter-
vention), and retention post-screening (attended/
dropped-out). All breast cancer nurses who delivered
the intervention will also be invited for an interview.
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Phase 3: Evaluation
Quantitative analysis
Data collected from self-report questionnaires will be
quantitatively analysed using the STATA software [32].
A detailed CONSORT diagram will be completed with
fully annotated reasons for withdrawal from the study
and follow-up rates where possible. This will also in-
clude numbers referred onto further specialist services
during the study. Descriptive statistics of questionnaire
data will be reported and inferential statistics, including
mixed regression modelling, will investigate outcome
variable associations. Growth curve analysis (linear and
polynomial parameters), will be performed using MPlus
[33] to calculate the fear of cancer recurrence trajectory
and intercept link intervention and control groups.
Interclass correlation coefficient (ICC) will also be deter-
mined to estimate the potential power required for fu-
ture trials, based on the number of clusters and sample
size per cluster. The Monte Carlo modelling approach
within MPlus, advanced by Bolger and Laurenceau [34],
will be utilised to determine the sample size required to
estimate for a moderate effect of the difference in trajec-
tory (i.e. slope coefficient) between intervention and
control groups with covariates (age, treatment experi-
ence, disease severity). Alpha set to 0.05 (2-sided). Ana-
lysis will not be blinded and will be conducted by the
local research teams (St Andrews and Stirling Univer-
sities) who will seek advice from a divisional statistician
(St Andrews).
Fidelity of intervention
A fidelity measure has been designed to assess the
SBCNs’ adherence to the Mini-AFTERc intervention
manual [35]. The fidelity measure will be applied to
transcripts of the Mini-AFTERc intervention the audio
recordings collected during the trial. The fidelity meas-
ure assesses adherence to key components (e.g. duration
of discussion) of the intervention and scoring is in-
formed by the principles of therapeutic alliance [36].
Qualitative analysis of interviews
The primary aim of the interviews is to assess the ac-
ceptability of the intervention to participants and the
feasibility of incorporating the intervention into current
NHS service provision. All interviews will be recorded
on digital recorders and transcribed verbatim.
The interview schedule and analysis will be informed
by normalisation process theory and its four main tenets:
coherence, cognitive participation, collective action and
reflexive monitoring [37]. It provides a constructive
approach to explain and evaluate the underlying mecha-
nisms of the implementation process and the compo-
nents used to provide information for the optimisation
of trial parameters [37]. The research team has experience
of using NPT in the area of FCR among nurses [18]. How-
ever, further adaptation will be undertaken to align the
component parts for the participant interviews.
Pilot trial evaluation
A process of decision-making after pilot and feasibility
trials (ADePT) [38] will be used to evaluate the evidence
from this pilot trial. The 3 key steps of ADePT facilitate
the systematic appraisal of pilot and feasibility trials to
identify all potential problems and solutions to these
problems prior to the expansion of the trial. Findings
from the quantitative data and analysis of interview data,
from the perspective of patients and SBCNs, will support
the decision-making process.
Discussion
The Mini-AFTERc intervention has been designed to
provide current cancer care professionals with a struc-
tured framework for discussing FCR with patients and
assisting patients to address and reduce elevated levels
of FCR at the end of primary cancer treatment. To our
knowledge, Mini-AFTERc is the first brief FCR interven-
tion, designed to assist individuals to manage moderate
levels of FCR before they progress to more severe level
and require a more intensive face-to-face psychological
intervention. Preliminary feasibility work is promising,
suggesting that Mini-AFTERc can feasibly be integrated
into existing end-of-treatment cancer care practice, is
acceptable to current cancer care staff and can effect-
ively reduce FCR in patients affected by breast cancer
[17, 18]. The proposed pilot trial will allow us to expand
this feasibility work and determine the optimal approach
to assess Mini-AFTERc in a controlled trial format.
SBCNs working in the UK recognise FCR as a primary
concern of patient affected by cancer and many express
a desire to receive training and develop the skills to bet-
ter support patients with FCR [18]. The Mini-AFTERc
intervention training programme has been specifically
designed for SBCNs, to complement and develop the
supportive skills that they already possess and have de-
veloped through routine practice. This pilot trial aims to
further refine the Mini-AFTERc intervention training
programme by allowing participating SBCNs to deter-
mine the focus of training sessions and provide feedback
to the research team. Through this approach, we intend
to develop a comprehensive but flexible training
programme that can be appropriately and usefully deliv-
ered to SBCNs of different skill levels and across differ-
ent centres.
Our feasibility work has determined that SBCNs may
find the Mini-AFTERc intervention feasible and accept-
able; however, we have yet to more broadly determine
how patients may react to Mini-AFTERc. Involving pa-
tients at an early stage in research design is known to
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enhance the quality and appropriateness of research [39].
In keeping with our commitment to patient involvement
in the development of this protocol, we intend to conduct
comprehensive interviews with a representative sample of
patients who participate in this trial. These interviews will
explore patient thoughts about the Mini-AFTERc inter-
vention, in terms of acceptability and usefulness, as well as
their perceptions of participating in the trial. By consider-
ing and combining patient and nurse interviews with a
structured decision-making framework (ADePT), we in-
tend to refine the Mini-AFTERc intervention in addition
to the trial structure and processes.
With this pilot work, we intend to collect the neces-
sary data to design a large-scale randomised controlled
trial of the Mini-AFTERc intervention. We believe this
information will be beneficial for and of interest to pa-
tients affected by cancer as well as cancer services. We
expect that this pilot trial will demonstrate that Mini-
AFTERc is a feasible intervention that can be widely in-
tegrated into current cancer care practice and provide
much needed emotional support to patients who have
reached the end of cancer treatment.
Supplementary information
Supplementary information accompanies this paper at https://doi.org/10.
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